Merck Rises 11% YTD: Should Investors Buy, Sell or Hold the Stock?Zacks Investment Research • 04/21/26
Merck-Eisai's combination cancer therapy fails to meet main goals of late-stage studyReuters • 04/21/26
Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)Business Wire • 04/21/26
FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder CancerBusiness Wire • 04/20/26
European Commission Approves Merck's ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV SeasonBusiness Wire • 04/17/26
MRK, Daiichi's BLA for ADC Drug Gets FDA Priority Tag in Lung CancerZacks Investment Research • 04/14/26
Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer who Experienced Disease Progression on or After Platinum-Based ChemotherapyBusiness Wire • 04/13/26
Terns Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Terns Pharmaceuticals, Inc. - TERNBusiness Wire • 04/10/26
AZN vs. MRK: Which Oncology Stock Offers Better Investment Potential?Zacks Investment Research • 04/09/26
Merck (MRK) Stock Declines While Market Improves: Some Information for InvestorsZacks Investment Research • 04/07/26
Is It Too Late to Buy Costco or Merck? Are These Defensive Stocks Overbought?24/7 Wall Street • 04/07/26
Trump threatens 100% tariff on US drug makers that don't strike deals to lower pricesThe Guardian • 04/02/26